See more : M3-Brigade Acquisition III Corp. (MBSC-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Emmaus Life Sciences, Inc. (EMMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emmaus Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Telia Company AB (publ) (TELIA.ST) Income Statement Analysis – Financial Results
- Othania Globale Aktier AKL (WEIOGA.CO) Income Statement Analysis – Financial Results
- Aspire Mining Limited (AKM.AX) Income Statement Analysis – Financial Results
- Schweizerische Nationalbank (0QKG.L) Income Statement Analysis – Financial Results
- Scinai Immunotherapeutics Ltd. (SCNI) Income Statement Analysis – Financial Results
Emmaus Life Sciences, Inc. (EMMA)
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.60M | 18.39M | 20.61M | 23.17M | 22.75M | 1.32M | 128.50K | 85.10K | 100.10K | 135.10K | 130.90K | 115.00K | 745.90K | 638.50K | 700.10K | 773.50K | 238.40K | 0.00 | 0.00 | 0.00 | 6.80K | 7.89K | 8.28K | 14.26K | 20.00K |
| Cost of Revenue | 1.34M | 2.59M | 3.31M | 2.25M | 1.09M | 827.40K | 53.50K | 5.50K | 4.90K | 73.00K | 142.60K | 132.00K | 147.10K | 135.10K | 131.60K | 163.20K | 166.20K | 0.00 | 0.00 | 0.00 | 885.00 | 1.21K | 1.15K | 5.78K | 10.00K |
| Gross Profit | 28.26M | 15.80M | 17.30M | 20.92M | 21.66M | 488.10K | 75.00K | 79.60K | 95.20K | 62.10K | -11.70K | -17.00K | 598.80K | 503.40K | 568.50K | 610.30K | 72.20K | 0.00 | 0.00 | 0.00 | 5.91K | 6.68K | 7.13K | 8.48K | 10.00K |
| Gross Profit Ratio | 95.47% | 85.93% | 83.93% | 90.30% | 95.19% | 37.10% | 58.37% | 93.54% | 95.10% | 45.97% | -8.94% | -14.78% | 80.28% | 78.84% | 81.20% | 78.90% | 30.29% | 0.00% | 0.00% | 0.00% | 86.98% | 84.66% | 86.15% | 59.49% | 50.00% |
| Research & Development | 1.19M | 1.73M | 4.11M | 2.41M | 2.18M | 1.38M | 1.36M | 794.20K | 783.80K | 1.45M | 1.29M | 853.70K | 924.80K | 1.12M | 2.14M | 2.10M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.89M | 13.17M | 13.44M | 13.68M | 17.01M | 7.36M | 4.42M | 2.50M | 1.62M | 2.03M | 2.54M | 2.94M | 4.27M | 5.02M | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.40K | 15.55K | 20.00K |
| Selling & Marketing | 8.64M | 7.49M | 5.88M | 4.87M | 6.98M | 1.99M | 1.40M | 550.50K | 347.90K | 390.20K | 366.30K | 997.10K | 1.23M | 870.90K | 915.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.53M | 20.66M | 19.32M | 18.54M | 23.99M | 9.36M | 5.82M | 3.05M | 1.97M | 2.42M | 2.90M | 3.94M | 5.50M | 5.89M | 4.80M | 3.99M | 1.90M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Other Expenses | 0.00 | -3.98M | 0.00 | 0.00 | -3.34M | 0.00 | 0.00 | 306.70K | 0.00 | 44.10K | 0.00 | 0.00 | 381.70K | 0.00 | 320.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.72M | 22.39M | 23.43M | 20.95M | 26.17M | 10.73M | 7.18M | 3.85M | 2.75M | 3.88M | 4.19M | 4.79M | 6.43M | 7.01M | 6.94M | 6.08M | 3.34M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Cost & Expenses | 26.06M | 24.98M | 26.74M | 23.20M | 27.26M | 11.56M | 7.23M | 3.85M | 2.76M | 3.95M | 4.33M | 4.92M | 6.58M | 7.14M | 7.07M | 6.25M | 3.51M | 416.21K | 28.58K | 261.09K | 145.43K | 18.27K | 17.55K | 21.33K | 30.00K |
| Interest Income | 681.00K | 680.00K | 761.00K | 2.30M | 232.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 0.00 | 0.00 | 99.50K | 104.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 11.00 | 0.00 |
| Interest Expense | 7.38M | 5.01M | 3.10M | 5.99M | 27.39M | 86.30K | 6.60K | 2.72M | 257.40K | 0.00 | 1.29M | 0.00 | 7.57M | 1.67M | 2.14M | 0.00 | 115.60K | 18.53K | 30.57K | 4.51K | 725.00 | 458.00 | 203.00 | 0.00 | -10.00K |
| Depreciation & Amortization | 32.00K | 53.00K | 59.00K | 60.00K | 73.00K | 113.10K | 48.70K | 7.20K | 7.60K | 10.30K | 13.00K | 18.80K | 11.90K | 9.40K | 9.10K | 6.30K | 19.90K | 225.00K | 39.33K | 0.00 | 96.00 | 0.00 | 65.00 | 231.00 | -20.00K |
| EBITDA | 3.57M | -5.50M | -12.76M | 28.00K | -26.98M | -10.13M | -7.05M | -3.19M | -3.12M | -2.63M | -4.19M | -4.79M | -1.29M | -7.80M | -6.67M | -5.47M | -3.25M | 553.80K | -1.09M | -261.09K | -138.63K | -10.38K | -9.20K | -6.84K | -30.00K |
| EBITDA Ratio | 12.07% | -35.81% | -39.02% | 0.07% | -36.01% | -769.82% | -5,490.19% | -4,726.56% | -2,179.42% | -3,654.92% | 875.63% | -4,162.70% | -779.93% | -812.51% | -850.25% | -706.89% | -1,407.97% | 0.00% | 0.00% | 0.00% | -2,041.27% | -131.43% | -111.20% | -47.98% | -150.00% |
| Operating Income | 3.54M | -6.59M | -6.13M | -43.00K | -4.51M | -10.24M | -7.10M | -3.77M | -2.66M | -3.82M | -4.20M | -4.81M | -5.83M | -6.51M | -6.69M | -5.47M | -3.27M | -416.21K | -28.58K | -261.09K | -138.63K | -10.38K | -9.27K | -7.07K | -10.00K |
| Operating Income Ratio | 11.96% | -35.81% | -29.73% | -0.19% | -19.83% | -778.78% | -5,528.09% | -4,426.32% | -2,653.75% | -2,825.17% | -3,209.01% | -4,179.04% | -781.53% | -1,018.79% | -955.88% | -707.71% | -1,371.48% | 0.00% | 0.00% | 0.00% | -2,039.86% | -131.43% | -111.99% | -49.60% | -50.00% |
| Total Other Income/Expenses | -7.33M | -3.98M | -9.79M | 1.01M | -50.17M | -317.80K | -6.60K | -2.17M | -724.60K | 1.16M | -6.69M | 1.89M | -2.50M | -1.67M | -1.82M | 104.00K | -8.70K | -18.53K | 8.76K | -4.51K | -629.00 | -458.00 | -197.00 | 11.00 | -10.00K |
| Income Before Tax | -3.79M | -10.63M | -15.92M | 719.00K | -54.68M | -10.33M | -7.11M | -5.94M | -3.38M | -2.65M | -10.89M | -2.91M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -434.74K | -19.82K | -265.60K | -139.26K | -10.83K | -9.47K | -7.06K | -20.00K |
| Income Before Tax Ratio | -12.81% | -57.78% | -77.25% | 3.10% | -240.32% | -785.34% | -5,533.23% | -6,978.73% | -3,377.62% | -1,965.14% | -8,317.19% | -2,534.26% | -1,188.54% | -1,280.06% | -1,216.25% | -694.26% | -1,375.13% | 0.00% | 0.00% | 0.00% | -2,049.12% | -137.23% | -114.37% | -49.53% | -100.00% |
| Income Tax Expense | -59.00K | 60.00K | 25.00K | -381.00K | 164.00K | 1.90K | 2.60K | 2.00K | 5.00K | 5.20K | 800.00 | 1.90K | 1.30K | 800.00 | 7.20K | 1.40K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 20.00K |
| Net Income | -3.73M | -10.69M | -15.95M | 1.35M | -54.84M | -9.60M | -7.11M | -5.94M | -3.38M | -2.66M | -10.91M | -3.41M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -435.54K | -20.62K | -266.40K | -140.06K | -11.63K | -10.27K | -7.86K | -40.00K |
| Net Income Ratio | -12.61% | -58.10% | -77.37% | 5.84% | -241.04% | -729.66% | -5,535.25% | -6,981.08% | -3,376.02% | -1,970.98% | -8,332.62% | -2,962.43% | -1,188.71% | -1,280.19% | -1,217.28% | -694.44% | -1,375.46% | 0.00% | 0.00% | 0.00% | -2,060.89% | -147.37% | -124.03% | -55.14% | -200.00% |
| EPS | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| EPS Diluted | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| Weighted Avg Shares Out | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.59K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
| Weighted Avg Shares Out (Dil) | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.60K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
Emmaus Life Sciences gets marketing authorization from Kuwaiti authorities for Endari
Emmaus Life Sciences Inc (OTCQX:EMMA) announced that the Kuwaiti Ministry of Health has granted marketing authorization for the commercial distribution and sale of its Endari product in the Gulf country. The Torrance, California-based firm said it has received Registration Approval...
Emmaus Life Sciences receives first major purchase order in Saudi Arabia
Emmaus Life Sciences Inc said it has received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, where its drug Endari is available on an early access basis. The Torrance, California-based company said it also has been...
Emmaus Life Sciences says Q3 revenue boosted by sales of Endari in the United Arab Emirates
Emmaus Life Sciences Inc (OTCQX:EMMA) has reported net revenue of $4.9 million for the third quarter of 2022, nearly 15% higher than the $4.3 million recorded in the second quarter, boosted primarily by its sickle cell oral therapy Endari in the United...
Emmaus Life Sciences announces collaboration with Kier (Junior) Spates to educate and support patients with sickle cell disease
Emmaus Life Sciences Inc (OTCQX:EMMA) said it is collaborating with Steve Harvey Morning Show cast member Kier (Junior) Spates to share Spates' personal experience using the company's prescription L-glutamine oral powder Endari to treat his sickle cell disease (SCD) on the...
Emmaus Life Sciences reports Q2 2022 net revenue of $4.3M after sales of Endari sickle cell disease treatment to United Arab Emirates
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced its financial results for the three and six months ended June 30, 2022, which received a fillip from the marketing approval in May of its sickle cell disease treatment Endari in the United...
Emmaus Life Sciences says successfully expands market access to sickle cell treatment Endari in 1Q
Emmaus Life Sciences Inc (OTCQX:EMMA) co-founder and CEO Dr Yutaka Niihara has told investors that the commercial-stage biopharmaceutical company successfully expanded market and patient access to sickle cell treatment Endari during the first quarter. "Immediately after the United Arab Emirates,...
Emmaus Life Sciences to Present at Investor Conferences in May
TORRANCE, Calif. , April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced participation in the following investor conferences in May: May 3-4: Q2 Investor Summit...
Emmaus Life Sciences launches full-service telehealth solution with online access to sickle cell treatment Endari
Emmaus Life Sciences Inc has announced that it has launched an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScript IP Holdings, LLC. The telehealth program capitalizes on the expansion of telemedicine in the US...
Emmaus Life Sciences presents positive study data on Endari treatment in sickle cell patients
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced real-world data on the company's prescription-grade L-glutamine oral powder, Endari, in preventing acute complications from sickle cell disease and hemolysis in pediatric and adult patients in French Guiana and Qatar. The data was introduced by the...
Emmaus Life Sciences says it is making progress in expanding access to Endari as it reports FY2021 revenue of $20.6M
Emmaus Life Sciences Inc (OTCQX:EMMA) CEO Yutaka Niihara said the company has made substantial progress in expanding access to Endari for sickle cell disease patients over 2021. Recently, the Torrance, California-based firm presented data from a post-hoc analysis of the Phase...
Source: https://incomestatements.info
Category: Stock Reports